Basal cell epithelioma. Types, treatment methods, and prognosis

Area of Science:

• Dermatology
• Oncology

Background:

• Basal cell epithelioma (BCE) is the most frequent type of skin cancer.
• Primary, untreated BCE is typically managed with various standard treatments.
• Recurrent BCE presents significant therapeutic challenges.

Purpose of the Study:

• To review treatment modalities for basal cell epithelioma.
• To highlight the distinction in management between primary and recurrent BCE.
• To emphasize the need for aggressive therapy in recurrent cases.

Main Methods:

• Review of established treatment protocols for primary basal cell epithelioma.
• Analysis of therapeutic outcomes for recurrent basal cell epithelioma.
• Discussion of advanced treatment options for refractory BCC.

Main Results:

• Primary BCE demonstrates high cure rates (approaching 98%) with standard methods like curettage, excision, cryosurgery, and radiotherapy.
• Recurrent BCE is considerably more challenging to treat effectively.
• Aggressive therapies, such as chemosurgery, are indicated for recurrent BCE.

Conclusions:

• While primary basal cell epithelioma is effectively managed with conventional therapies, recurrent cases necessitate more intensive treatment strategies.
• Chemosurgery is a recommended aggressive approach for difficult-to-treat recurrent BCE.
• Effective management of BCE depends on distinguishing between primary and recurrent disease stages.